Group 1: Market Competition and Product Positioning - The sales of nerve injury repair drugs have maintained a rapid compound growth, with mouse nerve growth factor having a small market share due to late market entry and fewer manufacturers [1] - Among four domestic mouse nerve growth factor products, Sutai Shen's Sutai Sheng holds the leading market share [1] - Competition in the market is present but also signifies joint development and expansion of market share [1] Group 2: Sales Growth and Product Guidelines - Sutai Qing is currently the preferred medication for constipation in clinical guidelines, contributing to its rapid sales growth [1] - The company aims to continuously enhance sales revenue from Sutai Qing [1] Group 3: Investment and R&D Focus - The company is actively seeking domestic and international investment and acquisition opportunities for promising products or companies [2] - R&D investment is closely linked to project progress, with a strong emphasis on innovative R&D and maintaining a competitive environment for talent [2][3] - The company is developing a human nerve growth factor using recombinant gene technology, which offers advantages in homology compared to mouse nerve growth factor [2] Group 4: Financial Management and Incentives - The stock incentive expenses have been fully accounted for, with no further issues expected in the second half of the year [2] - Future consideration for a new stock incentive plan is planned [2] - Sales expense ratio is expected to remain stable [3]

证券代码：300204 证券简称:舒泰神 舒泰神（北京）生物制药股份有限公司 投资者关系活动记录表 编号：2015-004 | --- | --- | --- | |--------------|--------------------------|--------------------------------------------------| | | | | | 投资者关系活 | ■ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | 国泰君安、民生证券 | | | 时间 | 2015 年 08 月 25 | 日 | | 地点 | 公司会议室 | | | 上市公司接待 | | | | 人员姓名 | 马莉娜 | | | 投资者关系活 | | 公司经营情况、研发情况、投资德丰瑞概况、公司产品 | | 动主要内容介 | 情况等。 | | | 绍 | | | | 附件清单 | 调研纪要 | | | 日期 | 2015 年 08 月 25 | 日 | ...

Financial Performance - The company achieved total revenue of CNY 55,904.30 million in the first half of 2015, representing a year-on-year growth of 12.26% [2] - The net profit attributable to shareholders was CNY 10,929.33 million, marking an impressive increase of 80.90% compared to the same period last year [2] Marketing Strategy - The company has strengthened its market efforts, focusing on bidding and price maintenance across provinces, with successful bids and a controlled price reduction [2] - The sales team has improved efficiency through training and skill enhancement [2] Research and Development - The company is focused on market-driven new product development and improving R&D efficiency [2] - A knowledge property team is being established to support innovation and protect intellectual property [2] Market Competition - The market for nerve injury repair drugs is growing rapidly, with the company's product, Su Tai Shen, holding the largest market share among four competitors [3] - The company aims to expand its market share by leveraging the advantages of its products [3] Investor Insights - The company is considering a new equity incentive plan in the future [3] - The impact of medical insurance cost control is recognized as a long-term challenge, with strategies to adapt and enhance sales in smaller hospitals [3] Product Development - The company has invested CNY 50 million in Beijing Defengrui Biotechnology Co., which holds exclusive rights to develop and sell monoclonal antibody drugs in China [4] - The project is expected to enhance the company's competitive edge and improve investment returns [4] Hospital Coverage - The target is to cover approximately 8,000 hospitals, with 2,200 currently developed, focusing on secondary and tertiary hospitals [5] - The company plans to increase its presence in county-level hospitals [5] Product Applications - Su Tai Qing, aimed at treating constipation and bowel cleansing, has a market potential of approximately CNY 800 million [5] - The product is safe and effective for various patient groups, including the elderly and pregnant women [5] Market Potential for OAB - The global market for overactive bladder (OAB) drugs was valued at USD 2.724 billion in 2013, with a projected annual growth rate of 4% [8] - The estimated market potential in China for OAB treatment is around CNY 13.8 billion annually [8] Competitive Advantages - The company's product, Qusi Luan, is recognized for its strong efficacy and minimal CNS side effects, making it a leading M receptor antagonist [9] - It is the only M receptor antagonist that does not undergo liver enzyme metabolism, with no reported drug interactions [10]

Group 1: Company Overview - Company Name: Shuotai Shen (Beijing) Biopharmaceutical Co., Ltd. [2] - Stock Code: 300204 [1] - Stock Abbreviation: Shuotai Shen [1] Group 2: Investor Relations Activity - Activity Type: Specific Object Research [2] - Date of Activity: November 6, 2014 [3] - Location: Company Conference Room [2] Group 3: Participants - Participating Institutions: Huashang Fund, Xinhua Asset, CITIC Securities, Dongxing Securities, and others [2] - Notable Participants: Individual investors and various funds [2] Group 4: Discussion Topics - Main Content of Discussion: Sales situation, R&D status, product situation, equity incentive situation, acquisition status, etc. [2]

Financial Performance - The company achieved total revenue of 78,962.66 million yuan in the first three quarters of 2014, representing a year-on-year growth of 21.95% [2] - The net profit attributable to shareholders was 12,357.58 million yuan, reflecting a year-on-year increase of 7.65% [2] Marketing Strategy - The company has tailored product planning and academic promotion strategies based on market research, enhancing brand building [2] - Training and improvement of sales personnel's capabilities have increased overall sales team efficiency [2] - The company is optimizing sales channels to consolidate existing markets while actively exploring potential markets [2] Research and Development - Key R&D projects are progressing, with improvements in organizational structure and innovation environment [2] - The company is focusing on enhancing R&D efficiency [2] Product Performance - Sales of the product "Sutai Sheng" have increased by over 15% year-on-year [4] - The product is performing well in provinces such as Zhejiang, Guangdong, Beijing, Shanghai, and Shaanxi [4] - "Sutai Sheng" holds the largest market share among nerve injury repair drugs, despite competition [4] Competitive Landscape - The market for nerve injury repair drugs is experiencing rapid compound growth, with "Sutai Sheng" benefiting from its effectiveness and fewer side effects [4] - The product is recognized for its direct repair action on nerve damage, distinguishing it from other neuroprotective agents [4] Regulatory and Clinical Guidelines - "Shutai Qing" is included as a first-choice medication in clinical guidelines for constipation [5] - The product is deemed safe and effective for various demographics, including the elderly, pregnant women, and children [6] Future Considerations - The company is considering new stock incentive plans after completing the current stock incentive expense [7] - There is an ongoing search for promising products or companies for potential acquisition [7] Sales Model - The marketing model for "Sutai Sheng" primarily employs a self-operated plus招商 (investment attraction) approach [7] - "Shutai Qing" also utilizes a similar sales model, with significant contributions from self-operated sales [7]

舒泰神（北京）生物制药股份有限公司接待投资者调研纪要 投资管理有限公司、某个人投资者 舒泰神调研纪要 时间：2015 年 04 月 24 日 | --- | |------------------------------------------------------| | | | 光大证券、太平洋证券、东方证券、民生证券、国联证券、 | | 长城基金、天弘基金、中信产业基金、嘉实基金、摩根 | | 士丹利华鑫基金、富国基金、泰康资产、上海承周资产 | | 管理有限公司、北京嘉承金信投资有限公司、南山集团 | | 资本投资有限公司、天马资产管理有限公司、广州长金 | 接待人：马莉娜 一、董事会秘书马莉娜介绍 2015 年第一季度业绩情况： 2015 年第一季度，公司实现营业总收入 23299.18 万元，比去年 同期增长 7.76%；归属于上市公司股东的净利润为 5044.41 万元，比 去年同期增长 41.81%。 营销方面，不断强化市场工作，高度重视各省招投标、价格维 护工作；深入研究所处市场环境，针对不同区域市场制定产品策划 和学术推广策略，持续加强品牌建设；通过对销售人员能力与素质 的培训与提升，提高 ...

证券代码：300204 证券简称:舒泰神 舒泰神（北京）生物制药股份有限公司 投资者关系活动记录表 编号：2015-002 | --- | --- | --- | |--------------|--------------------------|--------------------------------------------------| | | | | | 投资者关系活 | ■ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | | 光大证券、太平洋证券、东方证券、民生证券、国联证 | | | | 券、长城基金、天弘基金、中信产业基金、嘉实基金、 | | | | 摩根士丹利华鑫基金、富国基金、泰康资产、上海承周 | | | | 资产管理有限公司、北京嘉承金信投资有限公司、南 | | | | 山集团资本投资有限公司、天马资产管理有限公司、 | | | | 广州长金投资管理有限公司、某个人投资者 | | 时间 | 2015 年 04 月 ...

证券代码：300204 证券简称:舒泰神 舒泰神（北京）生物制药股份有限公司 投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |--------------|--------------------------|--------------------------------------------------| | | | | | 投资者关系活 | ■ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | | 信诚人寿、泰达宏利基金、瑞泰人寿、中银国际、合众 | | | | 资产、中融人寿、星石投资、南方基金、常州投资集 | | | | 团、中国人寿资产管理、上海森钵投资、江苏省建工集 | | | 团装饰工程有限公司 | | | 时间 | 2015 年 03 月 18 | 日 | | 地点 | 公司会议室 | | | 上市公司接待 | 马莉娜 | | | 人员姓名 | | | | 投资者关系活 | | 产品情况 ...

Group 1: Sales and Market Position - Su Tai Shen's Su Tai Sheng sales volume in 2014 was 4,577,919 bottles [3] - Su Tai Sheng holds the largest market share among four domestic varieties of mouse nerve growth factor [4] Group 2: Product Development and Differentiation - The human nerve growth factor developed by the company is an upgraded product of mouse nerve growth factor, utilizing recombinant gene technology [5] - The human nerve growth factor has advantages in homology compared to mouse nerve growth factor [5] Group 3: International Expansion and Strategy - The U.S. subsidiary has established its work direction, completed site leasing and renovation, and initiated personnel recruitment [5] - The Hong Kong subsidiary aims to leverage the favorable business environment for international investment and financing activities in the biopharmaceutical field [6] Group 4: Product Safety and Efficacy - Mouse nerve growth factor is currently the clearest product for direct repair of nerve damage, with fewer adverse reactions and high safety, stability, and effectiveness [6] - Su Tai Qing is safe and effective for use by elderly individuals, pregnant women, and children [6] Group 5: Research and Development Investment - R&D investment is closely related to the progress and stages of R&D projects, with the company emphasizing innovative research without compromising investment due to external factors [6]